Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists uncover DNA's hidden role in Kids' gut disease

NCT ID NCT05916274

Knowledge-focused Sponsor: Centre Hospitalier Régional d'Orléans Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 40 children aged 6 to 17 with inflammatory bowel disease (Crohn's or ulcerative colitis) to understand how DNA that escapes from cells might make inflammation worse. Researchers analyzed blood, stool, and gut tissue samples to see if a specific pathway (cGAS-STING) is involved. The goal was to find new clues for better treatments, not to test a therapy directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

May 2023

Finished

Feb 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged from 6 years inclusive to 17 years inclusive * Boys and girls * Presenting an IBD or suspicion of IBD * Requiring a colonoscopy for diagnosis or follow-up or other reason (abdominal pain, diarrhoea, rectal bleeding, weight loss) not confirming the diagnosis of Crohn's disease or Ulcerative Colitis * Active IBD if: * CD: PCDAI score \>5 and CRP\>20mg/L and faecal calprotectin\> 400 µg/g * UC: PUCAI score\>10 and faecal calprotectin\>250 µg/g * IBD in remission if: * CD: PCDAI score\<5 and CRP\<20mg/L and faecal calprotectin\<400 µg/g * UC: PUCAI score \<10 and faecal calprotectin \< 250 µg/g * Patients and their parents who gave their consent to participate in the study Exclusion Criteria: * Refusal of the participant and/or one of his two parents * Body weight less than or equal to 20 kg * Blood hemoglobin level less than or equal to 9 g/dl * Refusal or contraindication to general anesthesia * Co-existing severe chronic pathology and/or treatment that could interfere with the results of the study; example: trisomy 21, treatment with growth hormone etc. * Protected person (under guardianship or curatorship) * Person under legal protection * Person not affiliated to a social security scheme * Pregnant or breastfeeding woman

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bites and Stings Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Crohn disease Inflammatory bowel diseases Ulcerative colitis

Contacts and locations

Locations

  • CHU Orléans

    Orléans, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.